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A large and diverse array of chemoattractants control
leukocyte trafficking, but how these apparently
redundant signals collaborate in vivo is still largely
unknown. We previously demonstrated an absolute
requirement for the lipid chemoattractant leukotriene
B4 (LTB4) and its receptor BLT1 for neutrophil recruit-
ment into the joint in autoantibody-induced arthritis.
Wenowdemonstrate thatBLT1 is required for neutro-
phils to deliver IL-1 into the joint to initiate arthritis.
IL-1-expressing neutrophils amplify arthritis through
the production of neutrophil-active chemokines
from synovial tissue cells. CCR1 and CXCR2, two
neutrophil chemokine receptors, operate nonredun-
dantly to sequentially control the later phase of
neutrophil recruitment into the joint and mediate all
neutrophil chemokine activity in the model. Thus, we
have uncovered a complex sequential relationship
involving unique contributions from the lipidmediator
LTB4, the cytokine IL-1, and CCR1 and CXCR2 che-
mokine ligands that are all absolutely required for
effective neutrophil recruitment into the joint.
INTRODUCTION
Leukocyte recruitment into tissue compartments is a tightly
regulated process central to all inflammatory responses (Luster
et al., 2005). This process is choreographed by a diverse array
of chemoattractants, including lipid metabolites (e.g., leukotri-
enes), proteolytic fragments of serum proteins (e.g., comple-
ment), and secreted chemotactic cytokines (e.g., chemokines).
These chemoattractants cooperate to control leukocyte
migration by activating a family of related chemoattractant G
protein-coupled receptors (GPCRs) (Shimizu, 2009; Viola and
Luster, 2008). Although chemoattractants appear to have over-
lapping functions in vitro, in vivo studies have uncovered
a complexity in the control of leukocyte migration not appreci-266 Immunity 33, 266–278, August 27, 2010 ª2010 Elsevier Inc.ated by in vitro chemotaxis assays. This undoubtedly reflects
the different temporal and spatial nature of chemoattractant
production and activity, inherent differences in the biophysical
properties of the different chemoattractants, and ligand-induced
regulation of chemoattractant receptor expression and function
in vivo.
The K/BxN model of inflammatory arthritis is an excellent
model in which to interrogate the complexities of the chemoat-
tractant receptor system in the fine control of leukocyte
trafficking in vivo. This murine model of arthritis bears important
clinical and histopathologic similarities to human rheumatoid
arthritis, with synovial pannus formation and bone and cartilage
erosions (Kouskoff et al., 1996). K/BxN mice produce antibodies
against glucose 6-phosphate isomerase (GPI), which selectively
deposit in the joints as immune complexes and fix complement
(Matsumotoet al., 2002). After receiving serum fromK/BxN trans-
genicmice containing arthritogenic anti-GPI, wild-type (WT)mice
develop an inflammatory arthritis clinically and pathologically
similar to the transgenic mice. The innate immune system is
required for inflammation in the serum transfer model. Neutro-
phils, Fcg receptors, IL-1, the adaptor protein MyD88, the alter-
native complement pathway, and the C5a receptor C5aR are all
required for the generation of arthritis, but T and B lymphocytes
are dispensable (Ji et al., 2002a, 2002b; Wipke and Allen, 2001).
We and others have recently contributed to the appreciation of
the complexity of chemoattractant control of leukocyte traf-
ficking in this model by discovering that the lipid chemoattrac-
tant leukotriene B4 (LTB4) and its high-affinity receptor BLT1
are absolutely required for the development of arthritis in the
K/BxN serum transfer model (Chen et al., 2006; Kim et al.,
2006). Although we found that neutrophils are required to both
express BLT1 and synthesize its ligand, LTB4, to sustain joint
inflammation, adoptive transfer of WT neutrophils into arthritis-
resistant BLT1 gene-deficient Ltb4r1/ mice restored arthritis
by inducing endogenous Ltb4r1/ neutrophil recruitment into
the joint. This indicated that BLT1-expressing neutrophils enable
other neutrophils to enter the joint via chemoattractant receptors
other than BLT1.
We have been developing the concept that diverse chemoat-
tractants, including lipids and chemokines, cooperate to control
leukocyte recruitment in vivo (Luster and Tager, 2004;
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BLT1 pathway recruits the first wave of antigen-specific T helper
2 (Th2) cells into the lung in sensitized mice after aerosolized
antigen challenge (Tager et al., 2003). These Th2 cells then
amplify Th2 cell recruitment through the induction of IL-4-induc-
ible chemokine production froma resident lung cell (Medoff et al.,
2009). In the current study, we have explored the hypothesis that
in the K/BxNmodel, the LTB4-BLT1 pathway delivers neutrophils
expressing IL-1 and chemokines into the joint, which in turn
amplifies and sustains neutrophil recruitment and inflammation
via both neutrophil-derived and IL-1-inducible chemokines.RESULTS
Exogenous IL-1b Restores Arthritis Susceptibility
to Ltb4r1/ Mice
Because IL-1 is known to be required for arthritis in the K/BxN
model (Ji et al., 2002b), and we previously demonstrated that
IL-1 was markedly decreased in the joints of arthritis-resistant
Ltb4r1/mice (Kim et al., 2006), we first tested whether exoge-
nous murine recombinant IL-1b (mIL-1b) could restore arthritis
in Ltb4r1/ mice. Injection of mIL-1b in addition to K/BxN
serum induced polyarthritis in Ltb4r1/ mice similar to age-
and sex-matched C57Bl/6 wild-type (WT) control mice that
received K/BxN serum (Figures 1A and 1B). Although the disease
course in Ltb4r1/ mice that received mIL-1b (mIL-1b /
Ltb4r1/) was almost identical to WT mice in the early phase,
arthritis resolved more quickly in Ltb4r1/ mice after the last
dose of IL-1b.
Histological analysis corroborated our clinical findings
(Figure 1C). The joints of WT arthritic mice demonstrated
characteristic inflammation with leukocytic infiltrates, synovial
hypertrophy, and joint erosion, which was absent or only mini-
mally present in Ltb4r1/ mice. However, after receiving
mIL-1b, Ltb4r1/ mice developed pathological changes similar
to those observed in WT mice, particularly early in disease.
Histological scoring confirmed similar inflammation and
cartilage and bone erosion in the synovium of WT controls and
mIL-1b/Ltb4r1/mice in theearly stagesofarthritis (Figure1D).
By day 12, the leukocytic infiltrates in the synovium of mIL-1b/
Ltb4r1/ mice were significantly reduced. Thus, exogenous
mIL-1b was able to bypass the requirement for BLT1 signaling,
at least transiently, to induce arthritis in Ltb4r1/mice.
To determine whether mIL-1b induced chemokine expression
in the synovium of Ltb4r1/mice, resulting in the recruitment of
Ltb4r1/ polymorphonuclear leukocytes or neutrophils (PMNs)
into the joint in a BLT1-independent manner, we examined the
expression of neutrophil-active chemokines in the three groups
of mice—WT, Ltb4r1/, and mIL-1b / Ltb4r1/—on day 4
after the injection of arthritogenic serum (Figure 1E). As
expected, Ltb4r1/mice showed a markedly attenuated induc-
tion of chemokines, IL-1b, and TNF-a compared to WT mice. In
mIL-1b/ Ltb4r1/mice, the levels of several neutrophil-active
chemokines, including CCL4 (MIP-1b), CXCL2 (MIP-2), and
CXCL1 (KC), were significantly upregulated compared to
Ltb4r1/ mice that did not receive mIL-1b. Notably, IL-1b and
TNF-a were not upregulated in mIL-1b / Ltb4r1/ mice
compared to Ltb4r1/ mice. Therefore, our findings suggestthat IL-1b acts downstream of BLT1 signaling to induce chemo-
kine production in synovial tissues during inflammatory arthritis.
To further analyze the importance of chemokines in the recruit-
ment of leukocytes into the joint, synovial fluid leukocytes were
isolated from the ankle joints and analyzed for chemokine
receptor expression. WT mice had greater amounts of all che-
mokine receptors tested (CCR1, CCR2, CCR5, CXCR2,
CXCR4, BLT1), whereas Ltb4r1/ mice showed significantly
lower amounts, indicating a lack of leukocyte infiltrate into the
joints of these mice. After injection of mIL-1b, there was a resto-
ration of all chemokine receptors in joint fluid leukocytes in
Ltb4r1/ mice, consistent with the restoration of leukocyte
recruitment into the joints. In particular, high amounts of CCR1
and CXCR2 were observed. Thus, mIL-1b functions to bypass
BLT1 and induce the downstream expression of neutrophil-
active chemokines, which further recruit PMNs via their specific
chemokine receptors.
Neutrophil-Derived IL-1 Is Sufficient to Restore Arthritis
Susceptibility in Ltb4r1/ Mice
We previously demonstrated that WT PMNs were able to restore
arthritis in Ltb4r1/mice (Kimet al., 2006). Having demonstrated
that exogenous IL-1b also restored arthritis in Ltb4r1/ mice
(Figure 1), we next tested whether PMNs were the source of IL-
1b. To determine this, bone marrow (BM) PMNs from either WT
or IL-1a/b-deficient (Il1a/Il1b/) mice were adoptively trans-
ferred into Ltb4r1/ mice, and WT and Ltb4r1/ mice without
adoptive PMN transfer served as controls. As predicted,
Ltb4r1/ mice that received WT PMNs (WT PMN/ Ltb4r1/)
transiently developed arthritis, with an early disease course that
was indistinguishable from WT mice, but their arthritis resolved
more quickly. In contrast, Il1a/Il1b/ PMNs could not restore
arthritis in Ltb4r1/ mice (Il1a/Il1b/ PMN / Ltb4r1/)
(Figures2Aand2B), indicating thatneutrophil-derived IL-1 is suffi-
cient to restore disease in Ltb4r1/mice.
Histological and chemokine analyses of these mice also
paralleled their clinical disease activity. Joints of WT mice and
WT PMN/ Ltb4r1/mice demonstrated characteristic inflam-
mation with leukocytic infiltrates, which were either absent or
minimally present in Il1a/Il1b/ PMN / Ltb4r1/ and
Ltb4r1/ mice (Figure 2C). We also evaluated the expression of
neutrophil-active chemokines 4 days after serum transfer
(Figure 2D). Although transfer ofWTPMN restored synovial tissue
chemokines inLtb4r1/mice toamounts seen inWTmice, trans-
fer of Il1a/Il1b/ PMN into Ltb4r1/mice did not achieve this
effect. Thus, neutrophil-derived IL-1 was sufficient to restore
synovial tissuechemokine inductionand leukocyte joint infiltration
after the administration of arthritogenic serum.
Activated PMNs Produce IL-1b
To demonstrate thatmurine PMNs produce IL-1b in the course of
K/BxN arthritis, synovial fluid (SF) leukocyteswere collected from
arthritic ankles of 8-week-old K/BxNmice. SFPMNswere subse-
quently purified by immunomagnetic isolation via the neutrophil-
specific antibody Ly6G to a purity of 95% (Figure S1 available
online). Quantitative PCR (qPCR) analysis confirmed high
amounts of IL-1b mRNA in SF PMNs (Figure 3A). We next
compared IL-1bmRNA in purified SF PMNs with total SF leuko-
cytes (Figure 3B) from the joints of WT mice on days 1, 3, 7,Immunity 33, 266–278, August 27, 2010 ª2010 Elsevier Inc. 267
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Figure 1. Exogenous IL-1b Bypasses BLT1 to Induce Arthritis in Ltb4r1/ Mice
(A and B) Clinical score. The development of arthritis was examined in four different groups of mice (WT, Ltb4r1/, mIL-1b / Ltb4r1/, and CP [carrier
protein]/ Ltb4r1/) after K/BxN serum transfer on days 0 and 2. The mIL-1b/ Ltb4r1/ mice were injected with murine recombinant IL-1b i.p. on days
0, 1, and 2, and the CP/ Ltb4r1/ mice were injected with the carrier protein BSA on the same days. Ankle thickness (A) and clinical score (B) of these
mice were assessed daily. n = 6–9 mice in each group, and data are representative of three independent experiments. WT versus mIL-1b / Ltb4r1/
p < 0.0001, Ltb4r1/ versus mIL-1b/ Ltb4r1/ p < 0.0001 by ANOVA.
(C) Histopathology. In separate experiments, mice from these groups were sacrificed 4, 8, or 12 days after initial serum transfer and ankles harvested, parafor-
maldehyde-fixed, and H&E stained (scale bar represents 100 mm).
(D) Histological scoring. The degree of inflammatory infiltrates, cartilage erosion, and bone erosion in the ankle sections of these mice was scored according to
established methods (Pettit et al., 2001). WT versus Ltb4r1/, *p < 0.0005; Ltb4r1/ versus mIL-1b/ Ltb4r1/, +p < 0.005, ++p < 0.05.
(E) Synovial tissue chemokine and cytokine levels. Four days after serum transfer, mice were sacrificed and ankle synovial tissue was harvested for chemokine
and qPCR analysis (n = 4–10 from two independent experiments).
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Figure 2. Neutrophil IL-1 Is Required to
Induce Arthritis in Ltb4r1/ Mice
(A and B) Clinical score. WT and Il1a/Il1b/
PMNs were adoptively transferred into
Ltb4r1/ mice (WT PMN / Ltb4r1/ and
Il1a/Il1b/ PMN / BLT1/) i.v. immediately
after K/BxN serum transfer on days 0 and 2. The
development of arthritis in these two groups of
mice was assessed daily and compared with WT
and Ltb4r1/ mice that received only K/BxN
serum transfer on days 0 and 2. n = 3–4 mice in
each group, and data are representative of three
independent experiments. p < 0.0001 between
all groups by ANOVA.
(C) Histopathology. In separate experiments, mice
from these four groupswere sacrificed 4 days after
initial serum transfer and ankles harvested, para-
formaldehyde fixed, and stained with H&E (scale
bar represents 100 mm).
(D) Synovial tissue chemokine and cytokine levels.
Four days after serum transfer, mice from all three
groups were sacrificed and ankle synovial tissue
harvested for chemokine qPCR analysis (n = 4–6
from two independent experiments). WT versus
Ltb4r1/, *p < 0.05, **p < 0.005, ***p < 0.0002;
Ltb4r1/ versus WT PMN / Ltb4r1/,
Dp < 0.05; WT versus IL-1a/b/ PMN /
Ltb4r1/, +p < 0.02, ++p < 0.0001.
All data are presented as mean ± SEM.
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Lipid-Cytokine-Chemokine Cascade in PMN Homingand 10 after K/BxN serum transfer. In purified SF PMNs, IL-1b
mRNA was detected as early as day 1 and peaked at day 7. In
bulk SF leukocytes, lower amounts of IL-1b mRNA was first de-
tected on day 3 and also peaked on day 7. Although IL-1b
mRNAwas detected in bulk SF leukocytes, it remained consider-
ably lower than in purified SF PMNs throughout the entire time
course. This is probably related to a dilution of PMNs with other
cells in the bulk synovial fluid, resulting in a dilution of IL-1b
mRNA. It also suggests that PMNs are probably themain cellular
source of IL-1b in the synovial fluid of these mice.
Having established the presence of IL-1b mRNA in SF PMNs,
we examined IL-1b protein expression in PMNs. We first
measured pro-IL-1b by using immunoblot analysis comparing
lysates of three different populations of cells: BM PMNs, SF
PMNs, and total SF leukocytes from K/BxN transgenic mice
(Figure 3C). Greater amounts of pro-IL-1b protein were detected
in SF PMNs, although it was not detected in BM PMNs. Consis-
tent with the RNA data, total SF leukocytes contained less IL-1b
protein than purified SF PMNs, again probably reflecting a dilu-
tion effect. The induction of pro-IL-1b in SF PMNs is probably
a result of stimulatory signals received in, or on the way to, the
arthritic joint. We next analyzed the spontaneous release of
IL-1b by PMNs, determining IL-1b concentrations in the super-
natants of purified BM PMNs and SF PMNs from K/BxN trans-
genic mice incubated ex vivo for 21 hr (Figure 3D). In agreement(F) Synovial fluid leukocyte chemokine receptor levels. Four days after serum tr
receptor qPCR analysis (n = 4–10 from two independent experiments).
For (E) and (F), WT versus Ltb4r1/, *p < 0.05, **p < 0.005; Ltb4r1/ versus mI
All data are presented as mean ± SEM.with our immunoblot results, IL-1b was detected in the superna-
tants of SF PMNs by ELISA, but not in the supernatants of BM
PMNs. Finally, we also identified IL-1b protein by ELISA in puri-
fied SF PMNs isolated from the joints of WT mice 7 and 10 days
after the injection of K/BxN serum (Figure 3E). On days 1 and 3
after serum injection, the recovery of synovial fluid neutrophils
was too low to detect IL-1b by ELISA.
To identify potential links between LTB4 and neutrophil
production of IL-1b, we also assayed supernatants of BM
PMNs and SF PMNs for LTB4 after 21 hr of ex vivo incubation.
Under these conditions, SF PMNs released significantly more
LTB4 compared with BM PMNs (Figure 3F). In a separate
experiment, SF PMNs were incubated in the presence of the
BLT1-specific antagonist CP-105,696, and IL-1b release was
assayed (Figure 3G). There was no difference in IL-1b release
between SF PMNs that were incubated in the presence or
absence of CP-105,696. Therefore, endogenously produced
LTB4 had no apparent autocrine or paracrine effect on IL-1b
production in SF PMNs ex vivo. We also tested the effect of
LTB4 on IL-1b mRNA and protein release in WT BM PMNs
(Figures 3H and 3I). LTB4 also had no effect on IL-1b mRNA or
protein amounts in neutrophils, suggesting that LTB4 is not the
stimulus for neutrophil IL-1b production in the K/BxN model.
Because Fcg receptors are essential for the pathogenesis of
serum transfer-induced K/BxN arthritis in which immuneansfer, mice were sacrificed and synovial fluid cells harvested for chemokine
L-1b/ Ltb4r1/, +p < 0.02; WT versus mIL-1b/ Ltb4r1/, Dp < 0.02.
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Figure 3. Synovial Fluid PMNs Constitutively
Release IL-1b
(A) Synovial fluid PMNs isolated from the joints of K/BxN
transgenic mice were assayed for IL-1bmRNA expression
by qPCR (n = 4 and is representative of two independently
performed experiments).
(B) The presence of IL-1b mRNA in bulk synovial fluid
leukocytes and purified synovial PMNs isolated from the
joints of arthritic C57Bl/6 mice at indicated time points
after initial serum transfer was determined by qPCR
(n = 4–7 per time point).
(C) BM PMNs, synovial fluid PMNs, and total synovial fluid
infiltrates were isolated from K/BxN transgenic mice, and
cell lysates were assayed for the presence of pro-IL-1b
by immunoblot. One of four independent experiments is
shown.
(D and F) BM PMNs and synovial fluid PMNs isolated from
K/BxN transgenic mice were incubated ex vivo for 21 hr,
and IL-1b (D) and LTB4 (F) in the supernatant was
measured by ELISA (n = 3 independent experiments).
(E) Purified synovial fluid PMN lysates harvested at indi-
cated time points after initial serum transfer were assayed
for IL-1b with ELISA (n = 4 per time point).
(G) PMNswere isolated from synovial fluid of ankle joints of
K/BxN transgenic mice and incubated for 21 hr in the pres-
ence of the BLT1 inhibitor CP-105,696 (10 mM) and IL-1b
release was assayed by ELISA (n = 3 independent exper-
iments).
(H) BM PMNs from WT mice were stimulated with LTB4
(100 nM) or LPS (10 mg/ml) for 3 hr after which RNA was
isolated and IL-1b mRNA assessed by qPCR (n = 3
independent experiments).
(I) BM PMNs from WT mice were stimulated with LPS
(10 mg/ml) and/or LTB4 (100 nM) for 20 hr and, where indi-
cated, 5 mM ATP was added for another hour. IL-1b
content in the supernatants was then determined by ELISA
(n = 5 independent experiments).
(J) BM PMNs from WT, Ltb4r1/, and Fcer1g/ mice
were stimulated with immobilized immune complexes
(IC) for 3 hr or left untreated as a control (Ctrl). RNA was
harvested and IL-1b mRNA expression determined by
qPCR (n = 3 independent experiments).
(K) BM PMNs from WT, Ltb4r1/, and Fcer1g/ mice
were stimulated with immobilized immune complexes
(IC) for 20 hr or left untreated, and IL-1b was measured
in the supernatant by ELISA (n = 5 independent
experiments).
For (D)–(G), *p < 0.05, **p < 0.01, ***p < 0.001 compared to
BM PMNs. For (H)–(K), *p < 0.05, **p < 0.01, ***p < 0.001
compared to control (Ctrl).
All data are presented as mean ± SEM.
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determined the ability of immune complexes (ICs) to induce
IL-1b release from neutrophils. BM-derived PMNs from WT
and Ltb4r1/mice andmice deficient in the Fc receptor gamma
chain (Fcer1g/) were incubated with immobilized ICs. ICs
stimulated IL-1b mRNA accumulation in WT and Ltb4r1/ BM
PMNs but not in Fcer1g/ BM PMNs (Figure 3J). Consistent
with these RNA data, ICs stimulated IL-1b protein release from
WT and Ltb4r1/ BM PMNs but not from Fcer1g/ BM
PMNs (Figure 3K). These data demonstrate that ICs induce
IL-1b release from PMNs via FcR activation, as indicated by
the fact that IL-1b was not produced by Fcer1g/ PMNs. In
contrast, Ltb4r1/ PMNs produced similar levels of IL-1b270 Immunity 33, 266–278, August 27, 2010 ª2010 Elsevier Inc.mRNA and protein secretion compared with WT PMNs, demon-
strating that the LTB4-BLT1 pathway also does not play an indi-
rect autocrine or paracrine role in immune complex-mediated
IL-1b production and release by PMNs (Figures 3J and 3K).
Chemokine Induction in Synovial Tissue and Infiltrating
Synovial Fluid Leukocytes
We next examined the regulation of chemokine production in the
synovia of arthritic WTmice. At different time points (days 1, 3, 7,
and 10) after the transfer of arthritogenic serum into WT mice
(corresponding to preclinical, early onset, early peak, and estab-
lished peak disease activities, respectively), synovial tissue was
harvested and analyzed for chemokine RNA. We focused on the
Immunity
Lipid-Cytokine-Chemokine Cascade in PMN Homingligands for the two main murine neutrophil chemokine receptors
CCR1 and CXCR2, because the neutrophil is the main effector
cell that drives arthritis in this model. The murine CCR1 ligands
include CCL3 (MIP-1a), CCL4 (MIP-1b), CCL5 (RANTES), and
CCL9 (MIP-1g), and the murine CXCR2 ligands include CXCL1
(KC), CXCL2 (MIP-2), CXCL5 (LIX), and CXCL7 (NAP-2). Synovial
tissue chemokine RNA amounts were modulated differently over
time (Figure 4A). At day 1, several neutrophil-active chemokines,
including the CCR1 ligands CCL4, CCL3, and CCL5 and
the CXCR2 ligand CXCL2, were expressed. CCR1 ligands
peaked at day 7 whereas CXCR2 ligands continued to increase
over time. We also examined chemokine protein in the synovial
fluid by ELISA (Figure 4B). Consistent with the RNA data,
CCR1 and CXCR2 chemokine ligands were detectable by days
1 to 3 and peaked at day 7 with the exception of CXCL2, which
continued to rise on day 10.
Chemokine expression in synovial fluid leukocytes was also
examined, because leukocytes themselves are a potentially
important source of chemokines that amplify inflammatory
responses (Figure 4C). Chemokine RNA expression in total bulk
leukocytes from joint fluid of inflamed ankles of WT mice was
examined at different time points after serum transfer. At day 1,
CCL4 was the most highly expressed chemokine in leukocytes
recovered from the joint, but it did not increase andwasundetect-
able by day 10. In contrast, CXCL2 increased dramatically start-
ing on day 3 and remained very high through day 10.
To determine whether PMNs themselves also contributed to
chemokine production in the joint, PMNs were purified from the
synovial fluid and subjected to qPCR analysis (Figure 4D). Inter-
estingly, CXCL2 mRNA was markedly enriched in purified
PMNs isolated at all time points, suggesting that PMNs were
the main source of leukocyte-derived CXCL2. In contrast, the
CCR1 ligand CCL4 was not enriched in the PMN fraction until
day 4, suggesting that the earliest source of CCL4 is a leukocyte
other than the PMN. Chemokine protein in lysates of purified
PMNs from inflamed joints after serum transferwasalso analyzed
by ELISA. CCR1 and CXCR2 ligands were detected in purified
PMNs starting on day 3 when enough PMNs could be recovered
for chemokine protein analysis (Figure 4E). Consistent with the
RNA data, CXCL2was themost abundant neutrophil-active che-
mokine ligand expressed in SF PMNs, although the difference in
protein concentration for CXCL2 compared to the other chemo-
kines was not as large as the difference in RNA expression.
Immunohistochemical staining of inflamed ankle sections also
confirmed chemokine expression at the protein level (Figure 4F).
CXCL1 expression was seen primarily in the synovial tissue,
whereas CXCL2 was primarily expressed by SF leukocytes.
This finding demonstrates that other structural cells of the joint
may also contribute to neutrophil recruitment by producing che-
mokines.
IL-1b Stimulates Chemokine Production in Endothelial
Cells, Fibroblast-like Synoviocytes, and Macrophages
To determine whether IL-1 delivered to the joint by neutrophils
could amplify neutrophil recruitment by inducing the release of
neutrophil-active chemokines from synovial tissue cells, we
determined the pattern of chemokine production in structural
cells of the joint, such as fibroblast-like synoviocytes (FLS),
endothelial cells (ECs), and macrophages (MØ), in response toIL-1b and TNF-a stimulation for 4 hr (Figure S2) and 16 hr
(Figure 4G). Interestingly, of the CXCR2 ligands, FLS expressed
mostly CXCL5 and CXCL1 and not CXCL2 in response to
IL-1 stimulation (Figure 4G; Figure S2). Resting and TNF-a-stim-
ulated FLS did not express detectable CXCR2 ligands. Of the
CCR1 ligands, only CCL5 was detected in FLS, and it was
predominantly induced by TNF-a, rather than IL-1. ECs demon-
strated a different pattern of chemokine production. Of the
CXCR2 and CCR1 ligands, IL-1b predominantly induced the
expression of CXCL1 and CXCL2 at 4 and 16 hr and CCL5 at
16 hr in ECs. MØ had a third pattern of induction. CCL9 and
CCL3,CCR1 ligands, andCXCL2, aCXCR2 ligand, were induced
by IL-1b andTNF-a, whereasCCL5was inducedbyTNF-a. Over-
all, both IL-1b and TNF-a significantly induced FLS, ECs, andMØ
to express neutrophil-active chemokines, with FLS having the
highest chemokineRNAexpression. Taken together, our findings
suggest that neutrophils promote their own recruitment into the
joint by releasing large amounts of CXCL2 and by releasing IL-
1, which further amplifies neutrophil recruitment by inducing
CXCL5 from FLS, CXCL1 from ECs, and CCL9 from MØ.
Chemokine Receptor Expression on Neutrophils
Recruited into the Joint
To establish the relationship between chemokine expression in
the arthritic synovium and the expression of their specific recep-
tors on leukocytes recruited into the joint, we analyzed chemo-
kine receptor expression on joint leukocytes and purified joint
neutrophils at different phases of disease after K/BxN serum
transfer by qPCR analysis (Figure 5A). On day 1, high CCR1
and CCR5 mRNA expression was detected in the synovial fluid
leukocytes. Low amounts of CCR2, CXCR2, and BLT1 were
also noted. As disease progressed, CCR5, CXCR2, and
CXCR4 expression increased, whereas CCR1 and BLT1 expres-
sion remained stable.
Chemokine receptor expression was also evaluated on
purified SF PMNs from arthritic joints (Figure 5B). We found
that CCR1, CXCR2, and CXCR4 were detectable as early as
day 1 after serum transfer and increased throughout the course
of arthritis. BLT1 was also expressed early, but by day 7 its
expression was not detectable in PMNs.
We also examined BLT1 and CXCR2 protein surface
expression by flow cytometry (FCM) analysis with specific
mAbs on BM and SF PMNs (Figures 5C–5F). Freshly isolated
BM PMNs expressed both BLT1 and CXCR2 on their surface,
supporting the notion that these receptors can participate in
the recruitment of PMNs into the joint in serum-induced
arthritis. However, the patterns of BLT1 and CXCR2 surface
expression were different. BLT1 was expressed on all BM
PMNs (Figure 5C), whereas CXCR2 was expressed on the
surface of a subpopulation of BM PMNs (Figure 5E). Consistent
with our RNA data, PMNs isolated from inflamed joints on day 8
after serum transfer had lost their expression of BLT1
(Figure 5D). In contrast, CXCR2 surface expression was now
detected on all PMNs recovered from inflamed joints
(Figure 5F). In addition, CXCR2 surface expression was also
higher than on BM PMNs. Unfortunately, we were unable to
investigate CCR1 surface protein expression resulting from
the lack of a suitable CCR1 antibody for FCM analysis. We
therefore evaluated the expression of CCR1 on BM PMNsImmunity 33, 266–278, August 27, 2010 ª2010 Elsevier Inc. 271
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Figure 4. Neutrophil-Active Chemokine Expression Follows Temporal and Cell-Specific Patterns in Serum Transfer Arthritis
(A–E) Chemokine RNA in synovial tissue (A), chemokine protein levels in synovial fluid (B), chemokine RNA in synovial fluid leukocytes (C), chemokine RNA (D), and
chemokine protein (E) in purified synovial fluid PMNs from the ankles of serum transfer arthritic mice wasmeasured at designated time points during the course of
arthritis by qPCR and ELISA (n = 4–7 per time point).
(F) Immunohistochemical staining for CXCL1 and CXCL2 were performed on arthritic ankle tissue sections 7 days after initial serum transfer. Data shown are
representative of at least two independent experiments. For each antibody, the left panel scale bars represent 100 mm and the right panel scale bars represent
20 mm.
(G) Production of neutrophil-active chemokines by purified primary mouse fibroblast-like synoviocytes, endothelial cells, and macrophages occurs after 16 hr of
stimulation with TNF-a or IL-1b (n = 3–10 from two independent experiments). IL-1b versus TNF-a, *p < 0.05, **p < 0.01, ***p < 0.001; IL-1b versus resting, +p <
0.05, ++p < 0.01, +++p < 0.001.
All data are presented as mean ± SEM.
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(Gao et al., 1997), CCR1 was constitutively expressed on
murine BM PMNs (Figure S3). These data suggest that during272 Immunity 33, 266–278, August 27, 2010 ª2010 Elsevier Inc.the course of inflammatory arthritis, BLT1 is downregulated
on PMNs found in the joint and PMNs expressing CXCR2 are
preferentially recruited into the inflamed joint at later time
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Figure 5. Leukocyte Chemoattractant
Receptor Expression Profiles Vary
throughout the Course of Arthritis
(A and B) Chemoattractant receptor RNA expres-
sion on (A) synovial fluid leukocytes and (B) puri-
fied synovial fluid PMNs from ankles of serum
transfer arthriticmicewasmeasured at designated
time points during the course of arthritis by qPCR
(n = 4–7 per time point).
(C–F) Surface protein expression of BLT1 (C andD)
and CXCR2 (E and F) on PMNs isolated from the
bone marrow (C and E) and synovial fluid (D and
F) of arthritic mice 8 days after serum transfer.
PMNs were assayed for levels of surface BLT1
and CXCR2 expression by flow cytometry on
Ly6G+CD11b+ cells in the granulocyte gate via
specific mAb. Specificity of BLT1 and CXCR2
mAbs was confirmed with corresponding isotype
controls and PMNs isolated from the bone marrow
of Ltb4r1/ (C) and Cxcr2/ (E) mice, respec-
tively (n = 3 mice).
All data are presented as mean ± SEM.
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Lipid-Cytokine-Chemokine Cascade in PMN Homingpoints. CCR1 is also expressed on BM PMNs and thus is also
available for participation in the recruitment of PMNs into the
joint.
CCR1 and CXCR2 Are Critical Receptors Downstream
of BLT1 for Neutrophil Recruitment
The differential cellular sources and timing of chemokine
production and chemokine receptor expression on PMNs in
the model suggest that individual chemokines exert different
roles in the recruitment of neutrophils during the initiation and
progression of disease. We studied the functional significance
of the two main murine neutrophil chemokine receptors, CCR1
and CXCR2, implicated in the model by using mice deficient in
either CCR1 or CXCR2 (Figure 6). Groups of Ccr1/ and
Cxcr2/mice in the C57BL/6 background as well as WT control
C57BL/6 mice were injected with arthritogenic serum and moni-
tored for the development of arthritis.Ccr1/mice had amarked
delay in the initiation of arthritis compared with WTmice (Figures
6A and 6B), with attenuated arthritis severity. In contrast, arthritis
development inCxcr2/mice was nearly indistinguishable from
WT mice during the early phase of disease (Figures 6A and 6B);
however, maximum arthritis severity never reached that seen in
WT mice and resolved much more quickly.
Histological analysis ofCcr1/ andCxcr2/micewasconsis-
tent with clinical measurements (Figure 6C); the joints of Ccr1/Immunity 33, 266–27arthritic mice demonstrated less robust
inflammation, synovial hypertrophy, and
joint erosion than WT mice, particularly in
early time points. In contrast, Cxcr2/
andWTmice had initially indistinguishable
inflammation scores at early points. How-
ever, as was seen clinically, the inflamma-
tion score in Cxcr2/ mice improved
dramatically by day 12. Interestingly, the
bone and cartilage erosion scores did not
improve as dramatically as the inflamma-tion score in Cxcr2/ mice. Taken together these data suggest
that CCR1 and CXCR2 both contribute to arthritis development
but exert their maximal activity at different time points.
To determine whether CCR1 and CXCR2 account for all of the
chemokine receptor activity needed for neutrophil recruitment
and arthritis development in the K/BxN serum transfer model,
we generated mice genetically deficient in both CCR1 and
CXCR2 (Ccr1/Cxcr2/). Peripheral blood analysis revealed
no abnormalities in complete blood count or absolute neutrophil
count (Figure S4). However,Ccr1/Cxcr2/micewere remark-
ably completely resistant to the development of arthritis (Figures
6A and 6B). Of the Ccr1/Cxcr2/mice tested (n = 9), only two
developed transient joint swelling and erythema that was limited
to one portion of the joint and resolved within a few days.
Histological scoring showed negligible inflammation and joint
destruction (Figures 6C and 6D). These data confirm a critical
and nonredundant role for CCR1 and CXCR2 in the recruitment
of neutrophils and induction and progression of joint inflamma-
tion in thismodel of arthritis, despite othermultiple active chemo-
attractant pathways.
DISCUSSION
We have used the K/BxN model of arthritis to study the complex
nature of chemoattractant regulation of neutrophil recruitment8, August 27, 2010 ª2010 Elsevier Inc. 273
4 days
8 days
12 days
     WT Ccr1 -/- Cxcr2 -/- Ccr1-/-Cxcr2 -/-
D
C
A B
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0 2 4 6 8 10 12 14 16 18 20
In
cr
ea
se
 in
 a
nk
le
 th
ic
kn
es
s 
(m
m
)
After serum transfer (days) After serum transfer (days)
WT
Ccr1-/-
Cxcr2-/-
Ccr1-/-Cxcr2-/-
0
2
4
6
8
10
12
0 2 4 6 8 10 12 14 16 18 20
C
lin
ic
al
 s
co
re
WT
Ccr1-/-
Cxcr2-/-
Ccr1-/-Cxcr2-/-
*
**
*
*
**
**
*
**
**
*
***
*
*
** **
*
*
**
*
*
*
**
0
0.5
1
1.5
2
2.5
3
3.5
4
4 8 12
In
fla
m
m
at
io
n 
sc
or
e
After serum transfer (days) After serum transfer (days) After serum transfer (days)
0
0.5
1
1.5
2
2.5
3
3.5
4
4 8 12
Ca
rti
la
ge
 e
ro
si
on
 
sc
or
e
0
0.5
1
1.5
2
2.5
3
3.5
4
4 8 12
Bo
n
e 
er
os
io
n
 
sc
or
e
WT
Ccr1-/-
Cxcr2-/-
Ccr1-/-Cxcr2-/-
Figure 6. CCR1 and CXCR2 Mediate Early and Late Phases of Serum Transfer Arthritis
(A and B) Clinical score. WT, Ccr1/, Cxcr2/, and Ccr1/Cxcr2/mice were injected with K/BxN serum on days 0 and 2, and the degree of swelling (A) and
clinical score (C) in ankles and forelimbs were measured daily. nR 6 mice per group and are representative of at least two independent experiments. p < 0.0001
between all groups by ANOVA.
(C) Histopathology. In separate experiments, mice from these four groups were sacrificed 4, 8, or 12 days after the first serum transfer, ankles were harvested and
paraformaldehyde fixed, and H&E-stained sections were analyzed (scale bar represents 100 mm).
(D) Histopathological scoring. The degrees of inflammatory infiltrates in the processed ankles of these mice were evaluated according to established methods. n
R 4 mice per group and are from at least two independent experiments, and statistical comparisons were made between the knockout and WT mice. *p < 0.05,
**p < 0.001, ***p < 0.0001.
All data are presented as mean ± SEM.
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inant effector cell and IL-1 is the predominant cytokine that are
both required for arthritis. In the present study, we have now274 Immunity 33, 266–278, August 27, 2010 ª2010 Elsevier Inc.linked these two required factors by finding that neutrophils
are the main source of IL-1b in this model. Neutrophils isolated
from the joints of arthritic mice spontaneously released IL-1b
Immunity
Lipid-Cytokine-Chemokine Cascade in PMN Homingwhereas bone marrow neutrophils from arthritic mice did not,
suggesting that factors in the joints of arthritic mice activate
neutrophils to synthesize and release IL-1b. We found that ICs,
and not LTB4, induced IL-1b release in BM PMNs in vitro, sug-
gesting that ICs, which are required to initiate arthritis in the
model, are the crucial physiological stimulus that induces IL-1b
release by PMNs. This is consistent with the findings that FcgR
is required for IL-1b production and arthritis development in
the model (Ji et al., 2002a).
Mast cells have also been shown to be an important source of
IL-1b in the model. The role of mast cells in the model has been
controversial, however, because the mast cell-deficient strains
WBB6F1-Kit
W/KitW-v and WCB6F1-Kit
Sl/KitSl-d have been shown
to be resistant to arthritis (Lee et al., 2002), whereas the mast
cell-deficient strain C57Bl/6-KitW-sh has been shown to be
completely susceptible to inflammatory arthritis in this model
(Zhou et al., 2007). Further studies suggest that these differences
may be related to the effect that these mutations have on other
cell lineages, such as the neutrophil lineage. For example,
KitW/KitW-v mice have an associated neutropenia, whereas
KitW-sh mice have an associated neutrophilia compared to WT
mice (Nigrovic et al., 2008). Thus, the mast cell might be an
important early source of IL-1b in a relatively neutrophil-deficient
environment, whereas the mast cell appears to be dispensable
for IL-1b production in a setting where neutrophils are not
limiting. This is consistent with the finding that in the mast cell-
deficient KitW/KitW-v strain, a single dose of exogenous IL-1b
was able to ‘‘jump start’’ arthritis and additional exogenous
IL-1b was not needed to maintain arthritis in this mast cell-defi-
cient strain (Nigrovic et al., 2007). This suggests that IL-1b was
being supplied by another cell type in the model, which we
suspect was the neutrophil. This is in contrast to what we found
for Ltb4r1/mice, where repeated doses of IL-1b were needed
to maintain arthritis, suggesting an ongoing requirement for
neutrophil-derived IL-1.
In addition to expressing IL-1b, we found that neutrophils
also directly deliver chemokines active on themselves into the
joint, adding another layer of complexity in the way their recruit-
ment is regulated. Neutrophils directly participated in their
own recruitment by expressing the CXCR2 ligand CXCL2 and
to a lesser extent the CCR1 ligand CCL3, and indirectly by
delivering IL-1b to the joint, thereby inducing the production of
neutrophil-active chemokines from structural cells of the joint.
In response to IL-1b, FLS produced CXCL1 and CXCL5, EC
produced CXCL1, andMØproduced CCL9. A further complexity
in the regulation of neutrophil recruitment was the observation
that the expression of different neutrophil-active chemokines
was regulated differentially over the course of disease. Of
the CCR1 ligands, CCL4 was expressed at very early time points
and from a leukocyte in the joint other than the neutrophil,
whereas CCL3 and CCL9 were expressed slightly later. CXCR2
ligand expression peaked at later time points, comprised
of CXCL2 from neutrophils and CXCL5 and CXCL1, both
IL-1b-inducible chemokines, from synovial tissue cells. These
findings suggest that different temporal and spatial patterns
of CCR1 and CXCR2 ligand expression contribute to the func-
tional usage of these two receptors and imply that despite
similar cellular distribution, CCR1 and CXCR2 have nonredun-
dant roles in vivo.By using mice deficient in CCR1, CXCR2, and both CCR1 and
CXCR2, we found that CCR1 plays an important role in the initi-
ation of arthritis, whereas CXCR2 was critical for the mainte-
nance phase of arthritis. In contrast to the many descriptions
of partial inhibition of neutrophil recruitment with inhibition or
deletion of CCR1 or CXCR2 individually, we demonstrated that
deletion of both CCR1 and CXCR2 completely inhibited neutro-
phil recruitment and thus the development of arthritis. These
data suggest that effective inhibition of neutrophil recruitment
to sites of inflammation and infection in humans may require
the inhibition of more than one neutrophil chemokine receptor.
However, the analogous receptors that mediate this process in
humans remain to be determined because the neutrophil che-
mokine system is not completely orthologous between mice
and humans. Of note, in humans, CXCR1 and CXCR2 are the
two main chemokine receptors constitutively expressed on
neutrophils whereas CCR1 is expressed on human neutrophils
only after stimulation with inflammatory mediators (Hartl et al.,
2008). In contrast, CCR1 and CXCR2 are the twomain inflamma-
tory chemokine receptors constitutively expressed on murine
neutrophils.
The differential requirement for BLT1 and CXCR2 is also
reflected in their differential expression on the surface of PMNs
as they travel from the bone marrow into the inflamed joint.
During the course of inflammatory arthritis, BLT1 is downregu-
lated on PMNs that have entered the joint by high concentrations
of LTB4 that are present in the arthritic joint in the model
(Chen et al., 2006). Ligand-induced receptor downregulation
and internalization has been well described for BLT1 (Goldman
and Goetzl, 1984). In contrast, the increase in CXCR2 surface
expression on joint PMNs compared to BM PMNs may reflect
the preferential recruitment of CXCR2 expressing PMNs once
inflammation in the joint is initiated, which would be consistent
with CXCR2 playing an important role in PMN recruitment at later
time points. The apparent absence of CXCR2 downregulation on
PMNs in the joint may be a reflection of insufficient local joint
concentrations of CXCR2 ligands to induce receptor
internalization, which have been reported to be 10-fold higher
than concentrations needed for CXCR2-mediated chemotaxis
(Rose et al., 2004).
Thus, we have found that a cascade of diverse mediators that
include a lipid (LTB4) and its chemoattractant receptor (BLT1),
a cytokine (IL-1b), and chemokines active on CCR1 and
CXCR2 collaborate to control neutrophil trafficking into the joint
and the development of arthritis in this model. This model is likely
to be incomplete, because we still have not accounted for how
the very first neutrophils enter the joint to become activated by
immune complexes to release LTB4 and IL-1. We know that
immune complex deposition occurs in Ltb4r1/ mice after
serum transfer (Kim et al., 2006), so it is possible that local
complement activation could play such an early role. The
complement receptor C5aR is required for arthritis development
in this model and is a functional chemoattractant receptor ex-
pressed on murine neutrophils, and thus may play a role
upstream of BLT1 and the chemokine receptors by attracting
the first neutrophils into the joint after serum transfer. In prelim-
inary experiments, however, we have found that the transfer of
WT neutrophils intoC5ar1/mice did not restore arthritis devel-
opment, suggesting that C5aR may be required on cell typesImmunity 33, 266–278, August 27, 2010 ª2010 Elsevier Inc. 275
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present we cannot determine precise role of C5aR for neutrophil
trafficking in the model.
Although the K/BxN serum transfer model sharesmany impor-
tant features with human rheumatoid arthritis (RA), there exist
some important differences in autoantibody specificities and
cytokine dependence. However, significant parallels between
the two diseases speak to certain underlying pathologic mecha-
nisms of inflammatory arthritis. Deposition of anti-GPI as
immune complexes in the joint is critical for inflammation in the
K/BxN model, and although anti-GPI is not a significant autoan-
tibody in human RA, synovial fluid is enriched in immune
complexes, including antibodies against citrullinated antigens,
which probably contribute to joint inflammation (Snir et al.,
2010). The success of therapy directed against TNF-a and the
relative failure of anti-IL-1b therapies in treating human RA has
been pointed out as another important discrepancy between
the model and the human disease. However, the K/BxN serum
transfermodelhassomepartialdependenceuponTNF-a (Ji etal.,
2002b), and the lack of success of IL-1b therapy for rheumatoid
arthritis may instead reflect suboptimal pharmacokinetics of
currently available anti-IL-1b therapies in the treatment of
arthritis, as shown by the fact that IL-1b is highly expressed in
human rheumatoid synovial samples (Firestein et al., 1990).
Furthermore, systemic anti-IL-1 therapies have been therapeuti-
cally beneficial in certain forms of arthritis, such as juvenile idio-
pathic arthritis and Still’s disease (Fitzgerald et al., 2005; Pascual
et al., 2005), suggesting that some forms of human arthritis may
be more dependent on IL-1 than others.
We suspect that ‘‘cascades of chemoattractants’’ may be
a general principle for how these large families of diverse mole-
cules with overlapping functions in vitro collaborate to control
leukocyte trafficking in vivo. Our data described here in immune
complex-induced arthritis and our prior studies in antigen-
induced asthma support a model where lipid mediators function
early to initiate inflammatory cell recruitment. This first wave of
cells then amplifies recruitment by directly releasing chemokines
in situ and by inducing the production of chemokines from
tissue-resident cells through the release of cytokines. The nonre-
dundant collaborative roles of lipid mediators and chemokines in
orchestrating leukocyte trafficking in vivo may relate to differ-
ences in their production and metabolism. Lipid mediators are
produced rapidly and because of their short half life are likely
to act locally, whereas chemokines are produced more slowly
and are capable of acting at farther distances because of their
longer half-life and have even been shown to communicate
with the bone marrow to mobilize responding cells into the circu-
lation (Serbina and Pamer, 2006). It will be of interest to explore
the relationship between lipid mediators, chemokines, and
complement further in the control of neutrophil trafficking in
this immune complex-mediated model.
EXPERIMENTAL PROCEDURES
Mice
K/BxN and Ltb4r1/ mice were generated and maintained in our laboratory
as described (Kim et al., 2006). Il1a/Il1b/ mice were obtained from Y.
Iwakura (Horai et al., 1998) (University of Tokyo). Cxcr2+/ mice (Cacalano
et al., 1994) in the C57BL/6 background were obtained from A. Richmond
(Vanderbilt University). Cxcr2/ mice were generated by crossing Cxcr2+/276 Immunity 33, 266–278, August 27, 2010 ª2010 Elsevier Inc.mating pairs in our laboratory. Ccr1/ (Gao et al., 1997) and Fcer1g/ (Takai
et al., 1994) mice in the C57BL/6 background were purchased from Taconic
Farms, Inc., and wild-type C57BL/6 mice were purchased from the National
Cancer Institute. Ccr1/Cxcr2/ mice were generated by crossing Ccr1/
and Cxcr2/ mice, and genotypes were confirmed by PCR. All experiments
were performed according to protocols approved by the Massachusetts
General Hospital Subcommittee on Research Animal Care.
Serum Transfer and Arthritis Scoring
Pooled serum from 8-week-old arthritic K/BxN mice was transferred into
recipient mice (150 ml) intraperitoneally (i.p.) on days 0 and 2. Ankle swelling
was measured with a pocket thickness gage (Mitutoyo). Clinical scoring for
each pawwasmeasured based on the following index: 0, no edema/erythema;
1, localized edema/erythema over one surface of paw; 2, edema/erythema
involving the entirety of one surface of paw; 3, edema/erythema involving
both surfaces of paw. Scores were added for all four paws for a composite
score.
IL-1b Administration
Murine recombinant IL-1b (mIL-1) (R&D) contained bovine serum albumin
(BSA) from Sigma-Aldrich as a carrier protein (CP) (50 mg of CP per 1 mg of
IL-1). mIL-1 was reconstituted at 10 mg/ml in sterile PBS containing 0.1% of
the same BSA that was used as its CP. mIL-1b/ Ltb4r1/ mice received
mIL-1b (2.5 mg) i.p. on days 0, 1, and 2, whereas CP / Ltb4r1/ mice
received an equivalent amount of CP (125 mg) in sterile PBS + 0.1% BSA i.p.
on these 3 days. On days 0 and 2, mIL-1b or CP was given 4 hr after K/BxN
serum transfer.
Histological Scoring and Immunohistochemical Staining
Dissected ankles were fixed in 4% neutral buffered paraformaldehyde, demin-
eralized in modified Kristensen’s solution, and stained with hematoxylin and
eosin (H&E). Histological scoring of inflammation, cartilage erosion, and
bone erosion were scored as follows: 0, normal; 1, minimal; 2, mild; 3,
moderate; 4, marked; 5, severe according to the criteria as described (Pettit
et al., 2001). For immunohistochemical staining, decalcified paraffin ankle
sections were stained with Vectastain ABC peroxidase kits and NovaRED
substrate (Vector Labs) with CXCL1 and CXCL2 antibodies (R&D Systems)
as primary antibodies. Negative controls had no primary antibody applied,
and immunostained sections were counterstained with Mayer’s hematoxylin.
RNA Isolation and Quantitative PCR
RNA of the synovial tissues and synovial fluid and their subsequent qPCR anal-
ysis was performed as described (Kim et al., 2006).
BM PMN Adoptive Transfer
BMPMNs were isolated according to established protocols as described (Kim
et al., 2006). A total of 5 3 106 PMNs in HBSS were injected into 8-week-old
recipient mice via tail vein on day 0 and 150 ml K/BxN serum was injected
via tail vein on days 0 and 2.
Immunomagnetic Isolation of PMNs
BM and SF PMNs used for RNA and protein isolation and all in vitro neutrophil
experiments were isolated with an immunomagnetic separation strategy.
Freshly harvested BM or SF leukocytes were first stained with phycoery-
thrin-conjugated Ly6G antibody (BD Biosciences) and PMNs were then iso-
lated with EasySep PE selection kits (Stem Cell Technologies). Purity was
>95% as assessed by flow cytometry (Figure S1).
Flow Cytometry
Cells were blocked with 2.4G2 anti-FcgIII/II receptor (BD Biosciences) and
stainedwith the following antibodies: FITC-conjugated anti-murine LyG6 (Bec-
ton Dickinson), APC-conjugated anti-murine CD11b (eBiosciences), biotiny-
lated anti-murine BLT1 (3D7, mouse IgG1 generated in BLT1 KO mice; B.H.,
unpublished data), or PE-conjugated anti-murine CXCR2 (R&D) or control bio-
tinylated mouse IgG1 (R&D) for BLT1 mAb or control PE-conjugated rat-IgG2a
(R&D) for CXCR2. After washing, BLT1 and its isotype control mAb were
incubated with PE-streptavidin. Cytofluorometry was performed with a
FACS Calibur Cytometer (Becton Dickinson) and analyzed with CellQuest or
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cells in the granulocyte gate of forward and side scatter plots.
Detection of Pro-IL-1b by Immunoblot
SF leukocytes were lavaged from the joints of K/BxN transgenicmicewith 50 ml
PBS, and BM from the samemice was harvested. BM and SF PMNswere puri-
fied with EasySep kits and lysed immediately with lysis buffer (150 mM NaCl,
1 mMCaCl2, 25 mM Tris-Cl [pH 7.4], and 1% Triton X-100) supplemented with
protease inhibitor cocktail (Roche, Nutley, NJ) and DTT, Na3VO4, PMSF (each
1 mM), and NaF (20 mM). Thirty microgram total protein/lane were used for
immunoblot analysis. Protein lysates were separated by 10% SDS-polyacryl-
amide gel electrophoresis (SDS-PAGE) and transferred onto a nitrocellulose
membrane (Bio-Rad). Pro-IL-1bwas detected with a primary rabbit polyclonal
antibody (Abcam) and detected with a horseradish peroxidase-labeled
secondary antibody (Bio-Rad) and a chemoluminescence detection kit (Amer-
sham). Blots were stripped and reprobed for b-actin with a murine monoclonal
antibody (Abcam) and a horseradish peroxidase-labeled secondary antibody
(Bio-Rad).
Detection of IL-1b Release by ELISA
Immunomagnetically purified PMNs from BM and joints of K/BxN transgenic
mice were incubated at a concentration of 2 3 106/ml in RPMI, 10% FCS,
10 mM HEPES, 100 U/ml penicillin, 100 mg/ml streptomycin at 37C, 5%
CO2 for 21 hr. Cell-free cell culture supernatants were harvested and assayed
for IL-1b (eBioscience) and LTB4 (R&D) content by ELISA. The BLT1 inhibitor
CP-105,696 was a generous gift from Pfizer. CP-105,696 (10 mM in DMSO)
was added to cell cultures at a final concentration of 10 mM. All samples
were adjusted to a final DMSO concentration of 0.1%.
Detection of Cytokines and Chemokines by Mulitplex Multi-Analyte
Profiling
BM PMNs were immunomagnetically purified and lysed as described above.
Ankle joints were repeatedly flushed with PBS containing 2% FCS and
1 mM EDTA until the recovered joint lavage fluid was relatively acellular. The
joint lavage fluid was centrifuged at 800 3 g for 5 min, the supernatant was
reserved, and the recovered volume was recorded. The remaining leukocyte
cell pellet was then used for immunomagnetic PMN purification. The number
of purified PMNs recovered in each individual BM and SF sample was calcu-
lated by flow cytometry with Polybead Polystyrene 15 mmMicrospheres (Poly-
sciences) as a reference standard. The resulting purified BM or SF PMN
sample was lysed with protein lysis buffer as described above. 25 ml of BM
and SF PMN lysates and supernatant from joint fluid lavage were assayed
for cytokines and chemokines with a Multiplex Multi-Analyte Profiling mouse
chemokine/cytokine panel (Millipore). Samples were run on a Luminex 200
machine (Luminex Corporation) and results were analyzed with Upstate Bead-
View software (Upstate Cell Signaling).
Immune Complex Stimulaton of PMNs
Immobilized immune complex (IC) were formed with human serum albumin
(HSA) and rabbit polyclonal anti-HSA IgG Abs (Sigma-Aldrich) on high-binding
96-well ELISA plates (Corning) with 20 mg/ml HSA in 50 mM carbonate/bicar-
bonate buffer (pH 9.6) overnight. Afterwards, wells were washed with PBS and
blocked for 1 hr with 10% FCS in PBS. Wells were washed again and incu-
bated with HSA Abs at a 1/400 dilution in PBS and PBS alone as control for
6 hr. After another wash, 100 ml of 106 BM PMNs/ml for RNA harvest and
100 ml of 5 3 106 BM PMNs/ml supernatant harvest were incubated for 3 hr
and 20 hr, respectively.
Primary Murine Cell Isolation and Cytokine Stimulation
All cells were derived from C57Bl/6 mice. For FLS, dissected ankle tissues
were digested in Type IV collagenase (Worthington Corporation) and adherent
cells maintained in DMEMwith 10% FCS, 2mM glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin, and 50 mM2-mercaptoethanol. FLSmonolayers were
cultured until confluent and used between the fourth and sixth passages.
Murine cardiac ECs were isolated from cardiac tissue digested in 0.2% (w/v)
collagenase (Roche) and immunomagnetically double-selected via PECAM-
1-coated- and ICAM-2-coated Dynal beads (Dynal Corporation). ECs were
grown in DMEM containing 20% FCS, 100 mg/ml porcine heparin, and100 mg/ml EC growth supplement (Biomedical Technologies) in gelatin-coated
tissue-culture flasks. Bone marrow-derived MØ were grown on non-tissue
culture-treated Petri dishes in RPMI with 10% FCS, 10 mM HEPES, 100 U/ml
penicillin, 100 mg/ml streptomycin in the presence of 10 ng/ml M-CSF (Pepro-
tech). After 7 days, MØ were replated at a concentration of 150,000 cells/ml
and stimulated with 10 ng/ml of murine IL-1b or TNF-a (R&D) 4 hr and 16 hr,
and cells were harvested for RNA with RNeasy kits (QIAGEN). Confluent layers
of FLS andECwere each incubatedwith 10 ng/ml IL-1b or TNF-a in their growth
media and similarly harvested.
Statistical Analysis
All data are presented as mean ± SEM. Comparisons were analyzed for statis-
tical significance by two-tailed Student’s t test and one-way ANOVA with
GraphPad Prism software, with p < 0.05 considered statistically significant.
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